Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Liabilities: 2022-2024

Historic Total Liabilities for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $80.0 million.

  • Day One Biopharmaceuticals' Total Liabilities rose 38.74% to $62.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.9 million, marking a year-over-year increase of 38.74%. This contributed to the annual value of $80.0 million for FY2024, which is 171.24% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Total Liabilities of $80.0 million as of FY2024, which was up 171.24% from $29.5 million recorded in FY2023.
  • Over the past 5 years, Day One Biopharmaceuticals' Total Liabilities peaked at $80.0 million during FY2024, and registered a low of $17.0 million during FY2022.
  • Its 3-year average for Total Liabilities is $42.2 million, with a median of $29.5 million in 2023.
  • Data for Day One Biopharmaceuticals' Total Liabilities shows a peak YoY spiked of 171.24% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Day One Biopharmaceuticals' Total Liabilities stood at $17.0 million in 2022, then surged by 73.34% to $29.5 million in 2023, then surged by 171.24% to $80.0 million in 2024.